186 related articles for article (PubMed ID: 25923950)
1. Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors.
Tintori C; La Sala G; Vignaroli G; Botta L; Fallacara AL; Falchi F; Radi M; Zamperini C; Dreassi E; Dello Iacono L; Orioli D; Biamonti G; Garbelli M; Lossani A; Gasparrini F; Tuccinardi T; Laurenzana I; Angelucci A; Maga G; Schenone S; Brullo C; Musumeci F; Desogus A; Crespan E; Botta M
J Med Chem; 2015 Jun; 58(11):4590-609. PubMed ID: 25923950
[TBL] [Abstract][Full Text] [Related]
2. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.
Fallacara AL; Passannanti R; Mori M; Iovenitti G; Musumeci F; Greco C; Crespan E; Kissova M; Maga G; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Botta M; Schenone S
Eur J Med Chem; 2019 Nov; 181():111545. PubMed ID: 31400706
[TBL] [Abstract][Full Text] [Related]
3. Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors.
Poli G; Lapillo M; Granchi C; Caciolla J; Mouawad N; Caligiuri I; Rizzolio F; Langer T; Minutolo F; Tuccinardi T
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):956-961. PubMed ID: 29747534
[TBL] [Abstract][Full Text] [Related]
4. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
Schenone S; Brullo C; Bruno O; Bondavalli F; Mosti L; Maga G; Crespan E; Carraro F; Manetti F; Tintori C; Botta M
Eur J Med Chem; 2008 Dec; 43(12):2665-76. PubMed ID: 18342402
[TBL] [Abstract][Full Text] [Related]
6. ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders.
Demuro S; Sauvey C; Tripathi SK; Di Martino RMC; Shi D; Ortega JA; Russo D; Balboni B; Giabbai B; Storici P; Girotto S; Abagyan R; Cavalli A
Eur J Med Chem; 2022 Feb; 229():114054. PubMed ID: 34959172
[TBL] [Abstract][Full Text] [Related]
7. Fyn kinase in brain diseases and cancer: the search for inhibitors.
Schenone S; Brullo C; Musumeci F; Biava M; Falchi F; Botta M
Curr Med Chem; 2011; 18(19):2921-42. PubMed ID: 21651487
[TBL] [Abstract][Full Text] [Related]
8. Identification of new Fyn kinase inhibitors using a FLAP-based approach.
Poli G; Tuccinardi T; Rizzolio F; Caligiuri I; Botta L; Granchi C; Ortore G; Minutolo F; Schenone S; Martinelli A
J Chem Inf Model; 2013 Oct; 53(10):2538-47. PubMed ID: 24001328
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
Wang SF; Zhu YL; Zhu PT; Makawana JA; Zhang YL; Zhao MY; Lv PC; Zhu HL
Bioorg Med Chem; 2014 Nov; 22(21):6201-8. PubMed ID: 25267006
[TBL] [Abstract][Full Text] [Related]
10. 2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors.
Dreassi E; Zizzari AT; Mori M; Filippi I; Belfiore A; Naldini A; Carraro F; Santucci A; Schenone S; Botta M
Eur J Med Chem; 2010 Dec; 45(12):5958-64. PubMed ID: 20970221
[TBL] [Abstract][Full Text] [Related]
11. Structure of human Fyn kinase domain complexed with staurosporine.
Kinoshita T; Matsubara M; Ishiguro H; Okita K; Tada T
Biochem Biophys Res Commun; 2006 Aug; 346(3):840-4. PubMed ID: 16782058
[TBL] [Abstract][Full Text] [Related]
12. Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.
Tintori C; Fallacara AL; Radi M; Zamperini C; Dreassi E; Crespan E; Maga G; Schenone S; Musumeci F; Brullo C; Richters A; Gasparrini F; Angelucci A; Festuccia C; Delle Monache S; Rauh D; Botta M
J Med Chem; 2015 Jan; 58(1):347-61. PubMed ID: 25469771
[TBL] [Abstract][Full Text] [Related]
13. Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.
Musumeci F; Fallacara AL; Brullo C; Grossi G; Botta L; Calandro P; Chiariello M; Kissova M; Crespan E; Maga G; Schenone S
Eur J Med Chem; 2017 Feb; 127():369-378. PubMed ID: 28076826
[TBL] [Abstract][Full Text] [Related]
14. New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies.
Choi WK; El-Gamal MI; Choi HS; Baek D; Oh CH
Eur J Med Chem; 2011 Dec; 46(12):5754-62. PubMed ID: 22014559
[TBL] [Abstract][Full Text] [Related]
15. Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
El-Moghazy SM; George RF; Osman EEA; Elbatrawy AA; Kissova M; Colombo A; Crespan E; Maga G
Eur J Med Chem; 2016 Nov; 123():1-13. PubMed ID: 27474918
[TBL] [Abstract][Full Text] [Related]
16. Identification of Hck inhibitors as hits for the development of antileukemia and anti-HIV agents.
Tintori C; Laurenzana I; La Rocca F; Falchi F; Carraro F; Ruiz A; Esté JA; Kissova M; Crespan E; Maga G; Biava M; Brullo C; Schenone S; Botta M
ChemMedChem; 2013 Aug; 8(8):1353-60. PubMed ID: 23813855
[TBL] [Abstract][Full Text] [Related]
17. A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia.
Laurenzana I; Caivano A; Trino S; De Luca L; La Rocca F; Simeon V; Tintori C; D'Alessio F; Teramo A; Zambello R; Traficante A; Maietti M; Semenzato G; Schenone S; Botta M; Musto P; Del Vecchio L
Oncotarget; 2016 Oct; 7(40):65171-65184. PubMed ID: 27566560
[TBL] [Abstract][Full Text] [Related]
18. Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment.
Molinari A; Fallacara AL; Di Maria S; Zamperini C; Poggialini F; Musumeci F; Schenone S; Angelucci A; Colapietro A; Crespan E; Kissova M; Maga G; Botta M
Bioorg Med Chem Lett; 2018 Nov; 28(21):3454-3457. PubMed ID: 30262428
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.
Chen DX; Huang J; Liu M; Xu YG; Jiang C
Arch Pharm (Weinheim); 2015 Jan; 348(1):2-9. PubMed ID: 25430493
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
